ArticleScientific reports2019
Identification and characterization of the lncRNA signature associated with overall survival in patients with neuroblastoma.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Deepening the Understanding of Platelet-Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis.Cancer reports (Hoboken, N.J.) · 2026Article
- LncRNA GAS6-AS1 enhances the progression of pediatric neuroblastoma by modulating miR-3200-3p.World journal of surgical oncology · 2026Article
- Unveiling the molecular landscape: Long non-coding RNAs in neuroblastoma (Review).Oncology reports · 2026Review
- A pseudouridine-related prognostic model of colorectal cancer based on single-cell sequencing analysis and transcriptome analysis.Scientific reports · 2026Article
- Integrated bulk and single-cell RNA sequencing reveals a cuproptosis-related LncRNA prognostic signature in neuroblastoma.BMC cancer · 2025Article
- Exploring prognostic implications of miRNA signatures and telomere maintenance genes in kidney cancer.Molecular therapy. Oncology · 2024Article
- A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML.Blood advances · 2024Article
- Prediction of extranodal extension in head and neck squamous cell carcinoma by CT images using an evolutionary learning model.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Artificial intelligence-driven pan-cancer analysis reveals miRNA signatures for cancer stage prediction.HGG advances · 2023Article
- Article
- Novel tumor necrosis factor-related long non-coding RNAs signature for risk stratification and prognosis in glioblastoma.Frontiers in neurology · 2023Article
- LncRNAs and CircRNAs in cancer.MedComm · 2022Review
- Long noncoding RNA LINC01296 regulates the cell proliferation, migration and invasion in neuroblastoma.Metabolic brain disease · 2022Article
- MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.Scientific reports · 2022Article
- Tracking the amino acid changes of spike proteins across diverse host species of severe acute respiratory syndrome coronavirus 2.iScience · 2022Article
- Survival estimation in patients with stomach and esophageal carcinoma using miRNA expression profiles.Computational and structural biotechnology journal · 2022Article
- Evolutionary Learning-Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma after Resection.Liver cancer · 2021Article
- Identification of the miRNA signature associated with survival in patients with ovarian cancer.Aging · 2021Article
- Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma.Frontiers in oncology · 2021Article
- Predicting the Risk Genes of Autism Spectrum Disorders.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is a commonly occurring cancer among infants and young children. Recently, long non-coding RNAs (lncRNAs) have been using as prognostic biomarkers for therapeutics and interventions in various cancers. Considering the poor survival of NB, the lncRNA-based therapeutic strategies must be improved. This work proposes an overall survival time estimator called SVR-NB to identify the lncRNA signature that is associated with the overall survival of patients with NB. SVR-NB is an optimized support vector regression (SVR)-based method that uses an inheritable bi-objective combinatorial genetic algorithm for feature selection. The dataset of 231 NB patients that contains overall survival information and expression profiles of 783 lncRNAs was used to design and evaluate SVR-NB from the database of gene expression omnibus accession GSE62564. SVR-NB identified a signature of 35 lncRNAs and achieved a mean squared correlation coefficient of 0.85 and a mean absolute error of 0.56 year between the actual and estimated overall survival time using 10-fold cross-validation. Further, we ranked and characterized the 35 lncRNAs according to their contribution towards the estimation accuracy. Functional annotations and co-expression gene analysis of LOC440896, LINC00632, and IGF2-AS revealed the association of co-expressed genes in Kyoto Encyclopedia of Genes and Genomes pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.